Skin Toxicity and Quality of Life During Treatment With Panitumumab for RAS Wild-Type Metastatic Colorectal Carcinoma: Results From Three Randomised Clinical Trials

Quality of Life Research - Netherlands
doi 10.1007/s11136-016-1288-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Relationship Between Tumour Response and Tumour-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials

Clinical Colorectal Cancer
OncologyGastroenterology
2019English

FOLFIRI Plus Panitumumab in the Treatment of Wild-Type KRAS and Wild-Type NRAS Metastatic Colorectal Cancer

World Journal of Surgical Oncology
SurgeryOncology
2018English

Metastatic Colorectal Carcinoma: Response to Panitumumab

Journal of the Bahrain Medical Society
2018English

Impact of Primary Tumour Location on Second- Or Later-Line Treatment Outcomes in Patients With RAS Wild-Type Metastatic Colorectal Cancer and in All Lines of Treatment in Patients With RAS Mutations in Four Randomised Panitumumab Studies

Clinical Colorectal Cancer
OncologyGastroenterology
2018English

Randomized Controlled Trial on the Skin Toxicity of Panitumumab in Japanese Patients With Metastatic Colorectal Cancer: HGCSG1001 Study; J-Stepp

Future Oncology
MedicineCancer ResearchOncology
2015English

Health-Related Quality of Life and Colorectal Cancer-Specific Symptoms in Patients With Chemotherapy-Refractory Metastatic Disease Treated With Panitumumab

International Journal of Colorectal Disease
Gastroenterology
2010English

Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-Line Cetuximab and Irinotecan

JAMA Oncology
Cancer ResearchOncology
2019English

Sequential HER2 Blockade as Effective Therapy in Chemorefractory, HER2 Gene-Amplified, RAS Wild-Type, Metastatic Colorectal Cancer: Learning From a Clinical Case

ESMO Open
Cancer ResearchOncology
2018English

Magnetic Resonance Imaging as an Early Indicator of Clinical Outcome in Patients With Metastatic Colorectal Carcinoma Treated With Cetuximab or Panitumumab

Clinical Colorectal Cancer
OncologyGastroenterology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy